TABLE 4.
Comparison of time to progression (TTP) in the dogs receiving toceranib phosphate (TOC)
| Variables (n) | TTP (days) median (range) | P value |
|---|---|---|
| Adverse events | ||
| Incidence of AEs | ||
| Presence (18) | 356 (36‐1095) | .64 |
| Absence (24) | 364 (47‐1095) | |
| Systolic blood a pressure | ||
| ≤136 mm Hg (21) | 324 (36‐1095) | .04 |
| >136 mm Hg (21) | 387 (48‐1095) | |
| Neutrophil count b | ||
| ≤4200/μL (21) | 398 (47‐1095) | .02 |
| >4200/μL (21) | 318 (36‐1095) | |
| Treatment protocol | ||
| Total dose c | ||
| ≤112 mg/kg (21) | 324 (36‐1095) | .01 |
| >112 mg/kg (21) | 398 (47‐1095) | |
| Administration period | ||
| ≤124 days (21) | 331 (36‐1095) | .05 |
| >124 days (21) | 379 (40‐1095) | |
a
Systolic blood pressure showed mean value measured during TOC treatment.
b
Neutrophil count showed mean value measured during TOC treatment.
c
Total dose of TOC which administrated as postoperative adjuvant treatment (dose of 112 mg/kg showed mean value in the dogs receiving TOC).